Randomized, multicenter, double-blind, placebo-controlled phase IIb study to evaluate the efficacy, safety and tolerability of AZD2693 in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with fibrosis and risk allele carriers of PNPLA3 rs738409 148M.
Project objectivesThe objectives of the projects are attributable to the fields of interest of the UDR of Clinical Medicine and Hepatology: 1. Innovative treatments of advanced metabolic liver disease (MAFLD/NASH) with international multicenter intervention trials; 2. Innovative treatments of Primary Biliary Cholangitis (PBC); 3. The scouting and the characterization of MAFLD/NASH and risk factors for the evolution of chronic liver disease, including any genetic predispositions; 4. The scouting of cases of chronic Hepatitis C Virus (HCV) infection that are today susceptible to effective and well-tolerated treatment, even in elderly patients or with advanced liver disease; 5. Characterization and innovative treatments of sarcopenia in advanced chronic liver disease or malignancy; 6. Characterization of malignant and benign hepatic nodules using non-invasive techniques of temporary elastometry. |
Start and end date |
| March 2023 - Ongoing |
Project Manager |
| Vespasiani - Principal Investigator |
Coordinating institution of the project |
| UCBM |
Funding source(s). |
| Astrazeneca |